SpyGlass Pharma, Inc. (SGP)

SpyGlass Pharma Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023
Net Income	-39.87	-29.16	-13.32
Depreciation & Amortization	0.61	0.27	0.12
Stock-Based Compensation	2.79	1.49	0.87
Other Adjustments	1.4	3.82	0.12
Change in Receivables	-0.01	-0.3	-0.09
Changes in Accounts Payable	0.55	1.34	0.17
Changes in Accrued Expenses	2.57	1.01	0.27
Changes in Other Operating Activities	-0.74	-0.49	-0.43
Operating Cash Flow	-32.7	-22.03	-12.28
Capital Expenditures	-0.79	-1.99	-0.22
Purchases of Investments	-17	-20.63	-34.04
Proceeds from Sale of Investments	6	44.88	13.77
Investing Cash Flow	-11.79	22.26	-20.49
Issuance of Common Stock	0.17	0.19	0.01
Repurchase of Common Stock	-1.45	-	-
Net Common Stock Issued (Repurchased)	-1.28	0.19	0.01
Issuance of Preferred Stock	127.34	-	40.01
Net Preferred Stock Issued (Repurchased)	127.34	-	40.01
Other Financing Activities	-1.47	-	-0.25
Financing Cash Flow	124.59	0.19	39.77
Net Cash Flow	80.09	0.42	7.01
Free Cash Flow	-33.49	-24.02	-12.49
Free Cash Flow Per Share	-15.11	-13.43	-7.19
Levered Free Cash Flow	-37.66	-29.03	-13.4
Unlevered Free Cash Flow	-39.24	-26.93	-14.31

Updated Mar 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q